Neutrophil Proteases Can Inactivate Human PAR3 and Abolish the Co-receptor Function of PAR3 on Murine Platelets

Summary

Three members of the protease-activated receptor family, PAR1, PAR3 and PAR4, are activated when thrombin cleaves the receptor N-terminus, exposing a tethered ligand. Proteases other than thrombin can also cleave PAR family members and, depending upon whether this exposes or removes the tethered ligand, either activate or disable the receptor. For example, on human platelets PAR1 is disabled by cathepsin G, although aggregation still occurs because cathepsin G can activate PAR4. The present studies examine the interaction of cathepsin G and a second neutrophil protease, elastase, with PAR3 using two model systems: COS-7 cells transfected with human PAR3 and mouse platelets, which express PAR3 and PAR4, but not PAR1. In contrast to human platelets, cathepsin G did not aggregate murine platelets, and prevented their activation only at low thrombin concentrations. Elastase had no effect on thrombin responses in mouse platelets, but when added to COS cells expressing human PAR3, both cathepsin G and elastase prevented activation of phospholipase C by thrombin. Notably, this inhibition occurred without loss of the binding sites for two monoclonal antibodies that flank the tethered ligand on human PAR3. We therefore conclude that 1) exposure to cathepsin G disables signaling through human PAR3, and prevents murine PAR3 from serving its normal role, which is to facilitate PAR4 cleavage at low thrombin concentrations, 2) elastase disables human, but not murine, PAR3, 3) in contrast to human PAR4, mouse PAR4 will not support platelet aggregation in response to cathepsin G, and 4) the inactivation of human PAR3 by cathepsin G and elastase involves a mechanism other than amputation of the tethered ligand domain. These results extend the range of possible interactions between PAR family members and proteases, and provide further support for species-specific differences in the interaction of these receptors with proteases other than thrombin.

Keywords

Proteases - protease-activated receptors - thrombin - cathepsin G

• References

• 1 Vu T-KH, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991; 64: 1057-68.
• 2 Nystedt S, Emilsson K, Wahlestedt C, Sundelin J. Molecular Cloning of a potential proteinase activated receptor. Proc Natl Acad Sci USA 1994; 91: 9208-12.
• 3 Ishihara H, Connolly AJ, Zeng D, Kahn ML, Zheng YW, Timmons C, Tram T, Coughlin SR. Protease-activated receptor 3 is a second thrombin receptor in humans. Nature 1997; 386: 502-6.
• 4 Kahn ML, Zheng Y, Huang W, Birgonia V, Zeng D, Moff S, Farese RV, Tam C, Coughlin SR. A dual thrombin receptor system for platelet activation. Nature 1999; 394: 690-4.
• 5 Xu W, Andersen H, Whitmore TE, Presnell SR, Yee DP, Ching A, Gilbert T, Davie EW, Foster DC. Cloning and characterization of human protease-activated receptor 4. Proc Natl Acad Sci USA 1998; 95: 6642-6.
• 6 Nystedt S, Emilsson K, Larsson AK, Strömbeck B, Sundelin J. Molecular cloning and functional expression of the gene encoding the human proteinase-activated receptor 2. Eur J. Biochem 1995; 232: 84-9.
• 7 Molino M, Barnathan ES, Numerof R, Clark J, Dreyer M, Cumashi A, Hoxie JA, Schechter N, Woolkalis MJ, Brass LF. Interaction of mast cell tryptase with thrombin receptors and PAR-2. J Biol Chem 1997; 272: 4043-9.
• 8 O’Brien PJ, Prevost N, Molino M, Hollinger MK, Woolkalis MJ, Woulfe DS, Brass LF. Thrombin responses in human endothelial cells: contribution from receptors other than PAR1 include the transactivation of PAR2 by thrombin-cleaved PAR1. J Biol Chem 2000; 275: 13502-9.
• 9 Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR. Pro-tease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 1999; 103: 879-87.
• 10 D’andrea MR, Derian CK, Letursq D, Baker SM, Brunmark A, Ling P, Darrow AL, Santulli RJ, Brass LF, Andrade-Gordon P. Characterization of pro-tease-activated receptor-2 immunoreactivity in normal tissues. J Histochem Cytochem 1999; 46: 157-64.
• 11 Hwa JJ, Ghibaudi L, Williams P, Chintala M, Zhang RM, Chatterjee M, Sybertz E. Evidence for the presence of a proteinase-activated receptor distinct from the thrombin receptor in vascular endothelial cells. Circ Res 1996; 78: 581-8.
• 12 Schmidt VA, Nierman WC, Maglott DR, Cupit LD, Moskowitz KA, Wainer J, Bahou WF. The human proteinase-activated receptor-3 (PAR-3) gene. Identification within a PAR gene cluster and characterization in vascular endothelial cells and platelets. J Biol Chem 1998; 273: 15061-8.
• 13 Ishihara H, Zeng D, Connolly AJ, Tam C, Coughlin SR. Antibodies to pro-tease-activated receptor 3 inhibit activation of mouse platelets by thrombin. Blood 1998; 91: 4152-7.
• 14 Nakanishi-Matsui M, Zeng Y, Sulciner DJ, Weiss EJ, Ludeman MJ, Coughlin SR. PAR3 is a cofactor for PAR4 activation by thrombin. Nature 2000; 404: 609-13.
• 15 Molino M, Blanchard N, Belmonte E, Tarver AP, Abrams C, Hoxie JA, Cerletti C, Brass LF. Proteolysis of the human platelet and endothelial cell thrombin receptor by neutrophil-derived cathepsin G. J Biol Chem 1995; 270: 11168-75.
• 16 Renesto P, Si-Tahar M, Moniatte M, Balloy V, Van Dorsselaer A, Pidard D, Chignard M. Specific inhibition of thrombin-induced cell activation by the neutrophil proteinases elastase, cathepsin G and proteinase 3: evidence for distinct cleavage sites within the aminoterminal domain of the thrombin receptor. Blood 1997; 89: 1944-63.
• 17 Sambrano GR, Huang W, Faruqi T, Mahrus S, Craik C, Coughlin SR. Cathepsin G activates protease-activated receptor-4 in human platelets. J Biol Chem 2000; 275: 6819-23.
• 18 Evangelista V, Rajtar G, De Gaetano G, White JG, Cerletti C. Platelet activation by fMLP-stimulated polymorphonuclear leukocytes: the activity of cathepsin G is not prevented by antiproteinases. Blood 1991; 77: 2379-88.
• 19 Vouret-Craviari V, Grall D, Chambard J-C, Rasmussen UB, Pouysségur J, Van Obberghen-Schilling E. Post-translational and activation-dependent modifications of the G protein-coupled thrombin receptor. J Biol Chem 1995; 270: 8367-72.
• 20 Kinlough-Rathbone RL, Perry DW, Packham MA. Contrasting effects of thrombin and the thrombin receptor peptide, SFLLRN, on aggregation and release of ¹⁴C-serotonin by human platelets pretreated with chymotrypsin or serratia marcescens protease. Thromb Haemost 1995; 73: 122-5.
• 21 Kimura M, Andersen TT, Fenton II JW, Bahou WF, Aviv A. Plasmin-platelet interaction involves cleavage of functional thombin receptor. Am J Physiol Cell Physiol 1996; 271: C54-C60.
• 22 Kinlough-Rathbone RL, Perry DW, Rand ML, Packham MA. Pretreatment of human platelets with plasmin inhibits responses to thrombin, but potentiates responses to low concentrations of aggregating agents, including the thrombin receptor activating peptide, SFLLRN. Thromb Haemost 1997; 77: 741-7.
• 23 Kuliopulos A, Covic L, Seeley SK, Sheridan PJ, Helin J, Costello C. Plasmin desensitization of the PAR1 thrombin receptor: kinetics, sites of truncation, and implications for thrombolytic therapy. Biochemistry 1999; 34: 4572-85.
• 24 Greco NJ, Jones GD, Tandon NN, Kornhauser R, Jackson B, Jamieson GA. Differentiation of the two forms of GPIb functioning as receptors for α-thrombin and vonWillebrand factor: Ca²⁺ responses of protease-treated human platelets activated with α-thrombin and the tethered ligand peptide. Biochemistry 1996; 35: 915-21.
• 25 Molino M, Bainton DF, Hoxie JA, Coughlin SR, Brass LF. Thrombin receptors on human platelets. Initial localization and subsequent redistribution during platelet activation. J Biol Chem 1997; 272: 6011-7.
• 26 Chuang TT, Sallese M, Ambrosini G, Parruti G, De Blasi A. High expression of β-adrenergic receptor kinase in human peripheral blood leukocytes. Isoproterenol and platelet activating factor can induce kinase translocation. J Biol Chem 1992; 267: 6886-92.
• 27 Hoxie JA, Ahuja M, Belmonte E, Pizarro S, Parton RG, Brass LF. Internalization and recycling of activated thrombin receptors. J Biol Chem 1993; 268: 13756-63.
• 28 Brass LF. More pieces of the platelet activation puzzle slide into place. J Clin Invest 1999; 104: 1663-5.